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Abstract
Angiogenesis has been regarded as essential for tumor growth and progression.
Studies of many human tumors, however, suggest that their microcirculation
may be provided by nonsprouting vessels and that a variety of tumors can grow
and metastasize without angiogenesis. Vessel co-option, where tumor cells
migrate along the preexisting vessels of the host organ, is regarded as an alter-
native tumor blood supply. Vessel co-option may occur in many malignancies,
but so far mostly reported in highly vascularized tissues such as brain, lung,
and liver. In primary and metastatic lung cancer and liver metastasis from dif-
ferent primary origins, as much as 10–30% of the tumors are reported to use
this alternative blood supply. In addition, vessel co-option is introduced as a
potential explanation of antiangiogenic drug resistance, although the impact of
vessel co-option in this clinical setting is still to be further explored. In this
review we discuss tumor vessel co-option with specific examples of vessel co-
option in primary and secondary tumors and a consideration of the clinical
implications of this alternative tumor blood supply.
Introduction
Angiogenesis, the development of new blood vessels fol-
lowing the proliferation of the endothelial cells of pre-
existing vessels, is regarded as a hallmark in cancer
development [1]. There is, however, evidence that both
primary tumors and metastases are able to progress with-
out angiogenesis. Examples of such tumors include sub-
groups of non–small cell lung tumors (NSCLC) [2, 3],
lymphoma [4], and glioblastoma multiforme (GBM) [5].
Furthermore, nonangiogenic metastatic tumors have been
described in lung [6], liver [7–9], and lymph nodes [10].
This challenges the hypothesis that angiogenesis is
required for tumor growth and suggests that the vascula-
ture of human tumors is more complicated than initially
anticipated.
Several types of nonangiogenic tumor vascularization
have been described and defined as seen in Table 1. Vas-
culogenic mimicry (VM) is a mechanism by which highly
aggressive tumor cells can form vessel-like structures
themselves, by virtue of their high plasticity. A review by
Paulis et al. [11] describes signaling pathways in VM and
its role in on-going cancer research. Another mechanism
is by intussusception where preexisting vessels split into
daughter vessels. In an interesting study by Gianni-Barri
et al. [12]: “To sprout or to split? VEGF, Notch and vas-
cular morphogenesis,” they explore intussusception as an
alternative tumor blood supply and the molecular regula-
tion of this process.
Vessel co-option (or vascular co-option) is a mecha-
nism in which tumors obtain a blood supply by hijacking
the existing vasculature and tumor cells migrate along the
vessels of the host organ. In this review we discuss possi-
ble mechanisms for vessel co-option in animal models
and describe examples of clinically detectable tumors per-
fused by vessel co-option. In addition to being important
in tumor progression, vessel co-option has been proposed
as a potential explanation of why antiangiogenic treat-
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ment has less of an effect than expected [13]. In a clinical
setting, a predictive biomarker for antiangiogenic therapy
is not established. Therefore, this issue is likely to be of
particular interest to investigators developing clinical trials
of drugs that target angiogenesis and for the development
of new approaches to the study of tumor angiogenesis.
Reliable identification of these tumors is essential for the
accurate assessment of antiangiogenic drugs in the most
suitable tumors: The review will also describe the mor-
phological growth patterns (GPs) and vascular phenotypes
associated with vessel co-option together with clinical
implications.
The keywords vessel co-option, nonangiogenic tumors,
and angiogenesis were used in a systematic PubMed
search and articles judged most relevant were reviewed
and included in this report. Table 2 shows original stud-
ies published in the last 10 years related to vessel
co-option found by the search criteria, and as indicated,
much of the recent research related to tumor vessel
co-option has used murine or cell line models. However,
there are some studies based on human tissue, but com-
pared to the high number of studies related to angiogene-
sis the focus on vessel co-option as an alternative tumor
blood supply has been rather limited. Although potential
vessel co-option is observed in many malignancies
(Table 2), not surprisingly, vessel co-option seems to be
most frequently observed in highly vascularized tissue
such as brain, lung, and liver, the former two being well
oxygenated, the latter with high nutrient load.
Animal Models of Tumor Vessel
Co-Option
Early observations in human brain tissue that demon-
strated how a subset of tumors initially grow by co-opting
existing host vessels inspired Holash et al. to do further
studies in murine models [5, 14]. Holash and coworkers
observed the process of vessel co-option to be followed
by vessel regression, tumor hypoxia, and the stimulation
of angiogenesis for further growth to be based on the rel-
ative expression of pro- and antiangiogenic endothelial
growth factors (angiopoietin-1 and -2 and vascular endo-
thelial growth factor, VEGF) [14]. Interestingly, in their
rat glioma model, the co-opted vessels of the early tumors
expressed high levels of angiopoietin-2, the natural antag-
onist to the angiogenic angiopoietin-1. As the tumors
grew and became increasingly hypoxic, VEGF expression
was seen at the hypoxic periphery of the larger tumors.
The process of vessel co-option was not limited to glio-
mas, as shown by using rat mammary adenocarcinoma in
the same model conditions. The adenocarcinomas rapidly
co-opted blood vessels. It might be argued that the spe-
cialized conditions in the brain do not accurately model
conditions elsewhere: The authors, however, injected
Lewis Lung Carcinoma cells intravenously to colonize the
lung with similar results.
The idea of initial vessel co-option was later supported
by Kusters et al. [15]. In one of several comprehensive
murine studies related to this topic done by this group,
they induced metastasis to mouse brain parenchyma by
injection of melanoma cell lines into the carotid artery.
Lesions with diameters up to 3 mm3 were formed show-
ing an infiltrative GP in the parenchyma, which exploited
preexisting brain vessels. There were no differences
between the intratumoral vessels and vessels in normal
brain (assessed by vessel diameter, pericyte coverage, and
state of endothelial activation) and they had the charac-
teristics of an intact blood–brain barrier and vessel den-
sity was slightly lower than in the surrounding normal
brain. Interestingly, when the injected melanoma cell lines
were engineered to express the potent angiogenic factor
VEGF165, despite endothelial cells being activated and
showing upregulation of kinase insert domain receptor
(KDR) and endothelial cells and their surrounding peri-
cytes responding to the VEGF by proliferation, there was
no induction of angiogenesis in terms of sprouting and





Vasculogenesis In developing mammalian embryo angioblasts differentiate into endothelial cells assembling into
vascular labyrinth. Distinct signals differentiate arterial or venous differentiation
V V
Angiogenesis Endothelial sprouting, the development of new blood vessels following the proliferation of the
endothelial cells of preexisting vessels
V V
Arteriogenesis Endothelial cell channels become covered by pericytes or vascular smooth muscle cells (VCAMs) V V
Intussusception Preexisting vessels split into daughter vessels V V
Vessel co-option Tumor cells hijack the existing vasculature. Tumor cell migration along the vessels of the host organ – V
Vascular mimicry Tumor cells form tubular structures themselves – V
Cancer stem-like cells
differentiate into ECs
Endothelial cells (ECs) derived from putative cancer stem cells – V
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branching of new vessels. Although challenged by other
investigators who have used the same rat glioma model
[16], Kusters et al. [15] suggest that tumor cells do have
the capacity to co-opt vessels, allowing nonangiogenic
growth, and the models begin to provide an explanation
of the molecular mechanisms behind the process.
More recent studies have also emphasized vessel
co-option as an important alternative blood supply and
provided further insight to this mechanism’s role in
tumor development. In a zebrafish study by Zhao et al.
[17] it was concluded that the vessel co-option and
angiogenesis have distinct contributions at the earliest
stage of microtumors initiation and metastasis. However,
they suggest that angiogenesis plays the critical role in
tumoral exponential growth, whereas the strategy of
co-opting host vessels is an alternative but essential choice
for tumor cells to survive. Interestingly, they also found
some tumor cells in brain co-opted vessels with vessel-like
pseudopodia making them cover the vessel surface maxi-
mally and obtain more support from the host, such as
nutrients and oxygen.
In addition, to further explore the role of vessel co-
option in tumor development, recent murine studies have
supported the idea that vessel co-option may be a poten-
tial explanation as to why antiangiogenic therapy in many
cases does not appear to be as beneficial as initially
expected. Franco et al. [18], by the use of a genetically
engineered mouse model of pancreatic neuroendocrine
tumors (PNET), observed that tumors refractory to VEG-
FR-2 blocking antibody treatment contained blood vessels
with a prolific investment of pericytes expressing
a-smooth muscle actin (a-SMA). The authors claim it is
likely that the blood vessels carrying a-SMA+ pericytes
present within resistant tumors are derived from co-opted
blood vessels. This conclusion is in agreement with a
murine melanoma study identifying blood vessels covered
by a-SMA+ pericytes as a particular feature of tumors
acquiring vascularization through a nonangiogenic mech-
Table 2. Original articles from a systematic search1 regarded as relevant to describe vessel co-option as an alternative tumor blood supply are
shown.
Reference Year Search1 Malignancy Human Murine Cell lines
Van den Eynden et al. [8] 2012 2 Liver metastasis from colorectal cancer (CRC) X
Budde et al. [26] 2012 1 Brain and bone metastasis from breast cancer X
Franco et al. [18] 2012 1 Pancreatic neuroendocrine tumors (PNAS) X
Budde et al. [28] 2011 1 Brain metastasis from breast cancer X
Zhao et al. [17] 2011 1 Malignant melanoma, breast, and colon cancer X
Di Tomaso et al. [31] 2011 1 Glioblastoma X
Auf et al. [20] 2010 1 Glioma X X
Kienast et al. [27] 2010 1 Brain metastasis from lung cancer and melanoma cell lines X
Helfrich et al. [19] 2010 3 Melanoma X X
Carbonell et al. [49] 2009 1 Brain metastasis from different malignancies X X X
Winkler et al. [50] 2009 1 Glioma X
Reiss et al. [51] 2009 1 Breast cancer X
Sardari et al. [24] 2008 3 Non–small cell lung cancer (NSCLC) X
Sardari et al. [6] 2007 2 Lung metastasis from renal cell carcinoma X
Offersen et al. [52] 2007 2 NSCLC X
Adighibe et al. [21] 2006 2 NSCLC X
Arismendi-Morillo et al. [53] 2005 1 Brain X
Renyi-Vamos et al. [54] 2005 2 NSCLC X
Hu et al. [29] 2005 2 NSCLC X
Paku et al. [55] 2005 3 Liver metastasis X X
Leenders et al. [38] 2004 1 Brain metastasis from malignant melanoma cells X X
Shieh et al. [56] 2004 2 Oral squamous cell carcinoma X
Sardari et al. [57] 2004 2 NSCLC X
Stessels et al. [7] 2004 2 Liver metastasis from CRC and breast cancer X
Guedj et al. [58] 2004 3 Lung cancer (bronchoalveolar carcinoma, BAC) X
Kaicker et al. [59] 2003 1 Neuroblastoma X
Leenders et al. [60] 2003 1 Brain metastasis from malignant melanoma X
Passalidou et al. [4] 2003 3 Non-Hodgkins lymphoma X
Human-, murine-, and cell line studies are included. Studies published last 10 years are shown.
1Search criteria – systematic search in PubMed January, 2013. Search 1: “vessel co-option” OR “vessel cooption” OR “vessel co option” AND
“cancer” – 370 hits, 20 regarded relevant, 14 last 10 years. Search 2: “non-angiogenic” OR “nonangiogenic” – 126 hits, 13 regarded as relevant,
9 last 10 years. Search 3: Cited in studies from Searches 1 and 2, 15 regarded relevant, 5 last 10 years.
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anism [19]. In this latter study, they also analyzed human
melanoma metastases taken at clinical relapse in patients
undergoing adjuvant treatment with bevacizumab, in
addition to the murine model in which melanomas devel-
oped spontaneously. In both settings, those tumors devel-
oping during anti-VEGF therapy were characterized by a
mature intratumoral vascular network showing low angio-
genic activity and this vascular phenotype was indepen-
dent of tumor volume or localization. However, there are
indications that also newly formed vessels may recruit
a-SMA+ pericytes. Therefore, SMA+ vessels are not neces-
sarily co-opted and SMA positivity is not a confirmed
definitive marker for co-opted vessels.
Interestingly, using both the chick chorioallantoic
membrane assay and a mouse orthotopic brain model,
Auf et al. [20] observed that inhibition of inositol-requir-
ing enzyme 1 (IRE1) correlated with downregulation of
proangiogenic factors and upregulation of antiangiogenic
gene transcripts. Blockade of IRE1 modified glioma
expansion by reducing angiogenesis and by promoting
tumor cell invasion. Furthermore, the glioma cells co-
opted the host vasculature and infiltrated the brain along
blood vessel tracks.
The three latter murine studies have been able to detect
vessel co-option as a potential explanation of why antian-
giogenic therapy may not work [18–20]. However, many
traditional tumor xenograft models involve the inocula-
tion of tumor cells in basically avascular subcutaneous
space making them induce angiogenesis without the
opportunity to use vessel co-option as an alternative
blood supply. This is important as many of the promising
preclinical studies of antiangiogenic drugs have been done
in such relatively avascular experimental tumors.
Identification of Tumor Vessel Co-
Option
Many strategies have been used to identify putatively
nonangiogenic tumors including microvessel density
(MVD) counting, markers of endothelial cell prolifera-
tion, morphology, and new imaging techniques. Unfortu-
nately, distinguishing newly formed (angiogenic) vessels
from mature “nonangiogenic” vessels co-opted by a
tumor is difficult.
However, many of the tumors that have been reported
to grow without angiogenesis have a distinctive morphol-
ogy which in many cases allows their identification by
light microscopy (Fig. 1). Nonangiogenic tumors of the
lung, for example, are characterized by the “chicken-wire”
appearance of the preserved alveoli through which they
grow [21–23]. Complicating the picture, tumors with a
mixed phenotype is often seen, suggesting that non-
angiogenic tumors, rather than being a distinct subtype of
tumor, are probably only one extreme of a fairly wide-
spread process occurring in many tumors particularly at
the active edge. In the mixed cases the vessel co-option
component often are observed at their actively growing
edges, with the more mature center showing a switch to
an angiogenic phenotype.
Studies of angiogenesis in human tissues have often
used the technique of MVD measurement as a benchmark
of angiogenic activity. However, the MVD of a tumor
does not necessarily correlate with angiogenic activity in
the tumor. A major drawback of the technique is in its
failure to take into account the potential presence in a
tumor of co-opted, mature vessels. Although tumor MVD
counts that are similar to those obtained for the normal
surrounding tissue may provide an indirect sign of non-
angiogenic growth, these need to be used in combination
with other methods of assessing angiogenesis. Several
antibodies including CD31, CD34, and vWF (von Wille-
brand factor)/FVIII (Factor VIII) are useful for staining
endothelium, but do not differentiate between mature
and immature blood vessels. Mature vessels are character-
istically surrounded by pericytes. When stained for
smooth muscle actin (SMA) nonangiogenic vessels show
greater levels of SMA than their less mature angiogenic
counterparts. LH39 is an antibody directed against an epi-
tope of the lamina lucida of the basement membrane and
is expressed by capillaries and small venules in normal tis-
sues. A study by Passalidou et al. [22] was carried out to
determine phenotype and LH39 was expressed by vessels
in normal and nonangiogenic tumors, but on only a small
minority of angiogenic tumor vessels.
The fraction of proliferating endothelial cells, high-
lighted by double immunoreactivity with endothelial cell-
specific antibodies such as CD34 or Factor VIII and
cycling nuclei-specific antibodies such as Ki67 or prolifer-
ating cell nuclear antigen (PCNA) has been proposed as a
more reliable measure of on-going angiogenesis than
MVD. Sardari et al. [24] used double immunostaining
with CD34 and Ki-67 antibodies to assess endothelial cell
proliferation fraction and classified NSCLC into GPs
based on morphological characteristics of the tumor tis-
sue at the invading front; alveolar nonangiogenic (co-
option), papillary intermediate (co-option and angiogene-
sis), and destructive angiogenic (angiogenesis).
Imaging techniques and functional imaging in clinical
trials of targeted therapies were recently reviewed and
imaging of angiogenesis and hypoxia was discussed [25].
Dynamic contrast-enhanced (DCE), magnetic resonance
imaging (MRI) is put forward as a perfusion imagining
technique able to exploit differences between “leaky”, dis-
organized, tumor neovessels, and normal, well-organized
vasculature. However, the picture is complex and in a
recent study by Budde et al. [26], the authors conclude
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that DCE-MRI seemed to be a good alternative to evalu-
ate bone metastasis from breast cancer, but less useful
monitoring brain metastasis from the same primary
tumor. Other imaging methods, however, have also been
explored. Kienast et al. [27] have established multiphoton
laser scanning microscopy to image single steps of mouse
brain metastasis formation in real time. In this model
they monitored arrest at vascular branch points, early
extravasation, persistent close contacts to microvessels,
and, finally, differentiating perivascular growth between
vessel co-option and early angiogenesis. Kienast and
coworkers observed that brain metastasis initially prolifer-
ating by co-opting vessels needed remodeling of the exist-
ing vasculature for the continuous growth of
micrometastasis. Furthermore, they found that successful
brain macrometastasis formation in mice given lung can-
cer cell lines was followed by angiogenesis. In mice
injected with melanoma cells, initially growing micro-
metastasis that later regressed was located in regions of
poor vascularization compared to those micrometastasis
that grew to macrometastasis, indicating vessel co-option
as pivotal for tumor development in this cells line.
Although the technique is intriguing and offers advanta-
ges in a mouse model setting, there is a long way to go
before it is practical in a clinical setting. In another mur-
ine study, Budde et al. [28] conclude that phase contrast
MRI is sensitive to vascular remodeling in co-opting
brain tumor metastasis independently of sprouting angio-
genesis, and may therefore be useful in preclinical studies
of angiogenic-independent tumors or in the monitoring
of continued tumor growth following antiangiogenic ther-
apy. However, in conclusion, several imaging techniques
are in use to evaluate antiangiogenic treatment and to dif-
ferentiate between angiogenesis and vessel co-option. Both
the tumor type and location seem to be an issue and fur-
ther studies are needed to explore and optimize their clin-
ical impact.
Metabolism, Inflammation, and
Apoptosis in Tumors With Co-Opted
Blood Supply
Together with inflammation, energy metabolism has been
introduced as a new hallmark of cancer and there is evi-
dence that metabolism is differently expressed in vessel
co-opted versus angiogenic tumors [1, 29]. cDNA micro-
array analysis has been carried out in our laboratory to
compare nonangiogenic with angiogenic lung tumors
[29]. Tumors with co-opted blood supply had higher lev-
els of genes coding for proteins involved in mitochondrial
metabolism. This finding suggests a more effective regula-
tion of the intracellular respiratory chain in these tumors.
A possible explanation may be that the oxygen tension
near normal vessels supports an increase in mitochondrial
function in co-opted tumors and allows neoplastic growth
without triggering angiogenesis. In angiogenic tumors,
there were higher levels of expression of genes coding for
membrane vesicles, angiogenesis, and remodeling- and
inflammation-related pathways, possible due to more
hypoxia. Supporting this finding, we observed a signifi-
cant lack of fibrosis/desmoplasia and a reduction in
inflammation in tumors with co-opted blood supply in
comparison to angiogenic tumors. This study also found
a differential expression of genes involved in the regula-
tion of apoptosis. The pattern of expression observed sug-
gests that more apoptosis occurs in angiogenic tumors, as
would be expected from hypoxia. Hypoxia-inducible fac-
tor (HIF) target genes can also be induced by many onc-
ogenes, so it will be of interest to investigate genetic
changes in these cancers. In conclusion, the tumors with
A B C
Figure 1. (A) Normal lung. Immunostaining for CD31 (antibody JC70) demonstrates the capillaries (in red) of the normal alveoli. (B) An
angiogenic tumor: The normal lung architecture is diffusely replaced. New vessels (in red) and stroma are produced intimately mixed with
neoplastic cells but without any recognizable architectural structure. (C) A nonangiogenic tumor. Section of lung in which a carcinoma is growing
by filling the alveolar spaces: staining for CD31 shows the co-opted alveolar vessels highlighting the normal lung architecture. In this case the
pattern is present throughout the whole lesion.
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co-opted blood supply in this study have reduced inflam-
mation, decreased apoptosis and efficient mitochondrial
metabolism, deduced from gene expression array. How-
ever, new studies are needed to confirm these results.
Primary and Metastatic Human
Tumors
The capillary network of the brain parenchyma is one of
the densest in the mammalian body and apparently a
good basis for vessel co-option. An early indication that
mechanism other than angiogenesis was important in
tumor vascularization was based on results showing that
the vascular density in human GBM was in the same
range as that of normal cerebral white matter [5]. Later,
several comprehensive murine studies have added new
knowledge to the impact of vessel co-option in brain
tumors [30]. Studies including patient samples have been
rare, but in a recent study the impact of antiangiogenic
treatment in patients with GBM was explored [31].
Autopsy tissues from recurrent glioblastoma multiforme
(rGBM) patients treated with pan-VEGF receptor tyrosine
kinase inhibitor cediranib were compared to tissue from
rGBM patients with standard care (surgery, radiation, and
chemotherapy). The authors claim to provide the first
morphological evidence that anti-VEGF treatment
changes the GP of rGBM in patients with decreased
microvascular proliferation, loss of pseudopalisading
necrosis, and diffuse spread into the adjacent normal
brain. Furthermore, they show that instead of switching
to alternative angiogenesis pathways, rGBMs exhibit a
more infiltrative phenotype and blood vessels with normal
molecular expression and morphology after antiangio-
genic therapy. However, the small number of autopsies
and rGBM heterogeneity warrants further studies to
confirm these findings.
As shown in Table 2, several studies have explored ves-
sel co-option in NSCLC and the prevalence of tumors
predominantly presenting a picture of vessel co-option
reported to be about 10–20%. Interestingly, a subtype of
NSCLC: bronchoalveolar carcinoma (BAC), has long been
known to grow along alveolar walls preserving rather than
destroying the original lung structure. Nonangiogenic
lung tumors, however, typically entirely fill the alveoli
and their histological subtype is clearly identifiable (e.g.,
squamous cell carcinoma or adenocarcinoma). In NSCLC
the prognostic impact of a vessel co-option pattern has
been addressed and although the results have been con-
flicting, several studies have found low degree of angio-
genesis (a low endothelial cell proliferation fraction) to be
associated with a poor prognosis [24].
Several studies have described nonangiogenic tumor
growth in liver metastasis (Table 2), and in a recent study
the histological GP of colorectal liver metastasis is also
shown to have a prognostic value [8]. The GPs were cate-
gorized according to the morphology of tumor liver paren-
chyma described in earlier similar studies: desmoplastic
pattern, the tumor was separated from the liver paren-
chyma by a layer of desmoplastic stroma infiltrated with
lymphocytes and nests of tumor cells; pushing pattern, the
liver plates were compressed, running parallel to the tumor
liver interface without desmoplastic stroma and only a mild
inflammatory infiltrate; and replacement pattern, tumor
cells and liver parenchyma were in close approximation
with no compression of the plates, no desmoplastic stroma,
or inflammatory infiltrate and the tumor cells replaced the
hepatocytes in the liver cell plates without destruction of
the liver architecture. Van den Eynden and coworkers con-
clude that the ones with a replacement GP (27.8%) are
nonangiogenic, whereas the ones with a pushing GP
(15.6%) are the most angiogenic with angiogenesis being,
at least partially, hypoxia driven. At 2 years of follow-up, a
GP with a pushing component was an independent predic-
tor of poor survival, suggesting that the pushing GP is
characterized by more aggressive tumor biology.
Another interesting question is whether metastases
from angiogenic primary tumors share the vascular phe-
notype of their primary. Studies of the vasculature of
metastases indicate that a switch to angiogenesis in the
primary tumor is not a prerequisite for tumor progres-
sion to metastasis. Edel et al. [32] compared levels of
angiogenesis in primary breast tumors and their matched
lymph node metastases by studying endothelial cell prolif-
eration and found no consistent association. Furthermore,
Naresh et al. [10] investigated lymph node metastases
from squamous cell carcinomas of the oral cavity and lar-
ynx which showed that metastatic tumors in lymph nodes
have low MVD and low fractions of proliferating endo-
thelial cells in comparison to the primary tumors. This
indicates that angiogenesis may not be necessary for the
growth of carcinoma metastases in the well-vascularized
environment of the lymph node. This is borne out by the
preferential location of metastatic cells in the highly vas-
cular paracortex rather than in the follicles [10]. In con-
clusion, tumor vascularization in a metastatic deposit is
likely to be dependent on other factors besides the angio-
genic capability of the clone from which it is derived.
Clinical Implications
As discussed, tumors do co-opt host tissue vessels, it
is not exceptional, and may be present in a large propor-
tion of tumors. In the last decade research related to
angiogenesis has been massive, but investigation related
to vessel co-option as an alternative blood supply for
tumor growth has been more limited.
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An interesting question is whether the same pathways
are activated in co-opted vessels as in angiogenesis. As
previously mentioned, the major players so far known for
helping endothelial cells to survive during co-option are
VEGF and angiopoietins. Ang-1 activates Tie-2 and favors
tumor vessel maintenance. However, upregulation of
Ang-2 disturbs the interaction between Ang-1 and Tie-2
and causes destabilization of capillary walls. If the goal is
to break down EC function one might think that a com-
bination of an Ang-2 stimulator or Ang-1 inhibitor with
a VEGF inhibitor may be an interesting approach. Target-
ing both angiopoietin/Tie2 and VEGF pathways is cur-
rently under investigation in phase I, II, and III studies
[33], but the impact of vessel co-opted tumors has not
been addressed. However, targeting angiopoietin/Tie2
pathway has been challenging as angiopoietins can exert
either pro- or antitumorigenic effects, depending on the
cellular context [33]. In addition, it is observed that
blocking VEGF signaling increases co-option and growth
of satellite tumors [34]. Furthermore, as previously men-
tioned, tissue from rGBM patients shows a picture consis-
tent with increased vessel co-option after treated with
pan-VEGF receptor tyrosine kinase inhibitor cediranib
[31]. Furthermore, in a murine GBM study, Lu et al. [35]
observed inhibition of VEGF signaling leading to a proin-
vasive phenotype in a subset of GBM patients treated
with bevacizumab. Although, whether this increased inva-
sion may facilitate vessel co-option remains unanswered.
Increased knowledge related to the impact of VEGF
inhibitors on co-opted vessels is therefore warranted.
Interestingly there are, to our knowledge, no other
growth factors associated with vessel co-option [36], but
this is probably due to few studies related to this topic.
We have, however, previously observed that tumors with
co-opted blood supply had higher levels of genes coding
for proteins involved in mitochondrial metabolism [29].
Furthermore, tumors with co-opted blood supply had
reduced inflammation and decreased apoptosis. These
results have to be validated and further explored, but if
there are such fundamental differences between tumors
predominantly with angiogenesis versus co-optioned
blood supply this may have major impact on targeted
therapy strategies.
Another immediate implication relates to surgical
resection of isolated secondary deposits. The phenomenon
of isolated organ metastasis usually involves one of the
three major organs discussed above: liver, lung, or brain,
and can be seen with several different tumor types, for
example, colorectal, breast, melanoma, and renal cancer.
In itself, this suggests the possibility that rather than
angiogenesis enhancing the colonization of multiple
organs, a few metastases have been able to co-opt pre-
existing vessels. Overall, therefore, the tumor may not
have such an aggressive phenotype. Patients who undergo
liver resection for hepatic metastasis from colorectal can-
cer (CRC) experience recurrence rates ranging 60–85%
[37]. Predictive biomarkers, including angiogenic factors,
have been investigated in this setting, but further well-
designed studies are necessary to clarify their clinical rele-
vance [37]. It would be of interest to investigate whether
there is an association between a vascular co-opted pat-
tern and recurrence rate after liver resection for hepatic
metastasis. For patients with colorectal liver metastasis,
studies have shown that there are many tumors with an
angiogenic phenotype: in contrast, the large majority of
cases with breast cancer had a co-opted vascular pattern
[7]. Although only speculative, this may be one of several
potential explanations why the VEGF inhibitor bev-
acizumab so far is proven more effective in metastatic
CRC compared to advanced breast cancer.
Some studies have indicated that vessel co-option is
typically located at the edge of tumors and, interestingly,
less effect of antiangiogenic treatment in the tumor
periphery is observed [38–41]. In a recent murine study,
using an experimental model of lung metastasis and the
FDA-approved antiangiogenic drug sunitinib, Welti et al.
[41] found in some tumors extensive central devascular-
ization, but that the rim of these refractory tumors con-
tinued to be well vascularized. Vessel co-option may be
one of several potential explanations for this observation.
In general, vessel co-option is only one of many related
mechanisms that may explain resistance to antiangiogenic
treatment, as for instance, other modes of tumor vascu-
larization (intussusception, vasculogenesis, and VM) [13],
alternative proangiogenic factors [42], vascular matura-
tion [43], activation of autophagy [44], or recruitment of
myeloid-derived suppressor cells [45].
However, as co-opted vessels are also important in
early stage of tumor development it would be of interest
to know whether vessel co-option partly may be one of
the reasons why antiangiogenic treatment has not
succeeded so far in an adjuvant setting [46–48].
Prospective studies to address whether co-opted vessels
are predictive for treatment response to antiangiogenic
drugs are of interest. In addition to antiangiogenic-
targeted therapy this also may be an issue in radiotherapy
where tumor tissue’s oxygen level is important for treat-
ment effect. As discussed there are several methods to
determine whether the vasculature is new or co-opted
and this would be valuable in drug development, ensuring
that appropriate patients were entered into clinical
trials and trial resources were used more effectively. In
addition to morphological characteristics and measuring
endothelial proliferation, imaging methods such as DCE,
MRI, or PET (positron emission tomography) probes for
hypoxia will be important to monitor vessel co-option/
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angiogenesis status in tumors prior to and during treat-
ment. Finally, more basic research on the underlying
mechanisms with regard to vessel co-option is pivotal to
develop potential new treatment strategies.
Conclusions
Some tumors, both primary and metastatic, use preexist-
ing host tissue vessels as their blood supply. In many
cases, however, there is a mixed phenotype of co-opted
vessels and angiogenesis. The fact that tumors may grow
to a clinically detectable size without angiogenesis makes
them less likely to respond to drugs designed to target
the abnormal vasculature produced by angiogenesis. Even
if only the invading edge of the tumor remains able to
progress without angiogenesis, one may speculate that
these drugs are likely to be ineffective. Despite massive
research on antiangiogenic treatment, the understanding
of vessel co-option is rather limited. There are indications
that other biological mechanisms are important in
tumors with co-opted blood supply than in angiogenic
tumors, and further studies to explore the biological and
clinical implication of these co-opted vessels are highly
warranted.
Acknowledgments
We want to thank Cancer Research U.K., Oxford NHS
Biomedical Research Centre, the Norwegian Cancer Soci-
ety and Northern Norway Health Region Authority for
help and financial support and, finally, Miss Louisa Chan-




1. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of
cancer: the next generation. Cell 144:646–674.
2. Pezzella, F., B. A. Di, S. Andreola, A. G. Nicholson, U.
Pastorino, and A. L. Harris. 1996. Angiogenesis in primary
lung cancer and lung secondaries. Eur. J. Cancer
32A:2494–2500.
3. Pezzella, F., U. Pastorino, E. Tagliabue, S. Andreola, G.
Sozzi, G. Gasparini, et al. 1997. Non-small-cell lung
carcinoma tumor growth without morphological evidence
of neo-angiogenesis. Am. J. Pathol. 151:1417–1423.
4. Passalidou, E., M. Stewart, M. Trivella, G. Steers, G. Pillai,
A. Dogan, et al. 2003. Vascular patterns in reactive
lymphoid tissue and in non-Hodgkin’s lymphoma. Br. J.
Cancer 88:553–559.
5. Wesseling, P., J. A. van der Laak, L. H. de Leeuw, D. J.
Ruiter, and P. C. Burger. 1994. Quantitative
immunohistological analysis of the microvasculature in
untreated human glioblastoma multiforme.
Computer-assisted image analysis of whole-tumor sections.
J. Neurosurg. 81:902–909.
6. Sardari, N. P., J. Hendriks, G. Friedel, S. P. Van, and M. E.
Van. 2007. Distinct angiogenic and non-angiogenic growth
patterns of lung metastases from renal cell carcinoma.
Histopathology 51:354–361.
7. Stessels, F., G. Van den Eynden, I. Van der Auwera, R.
Salgado, E. Van den Heuvel, A. L. Harris, et al. 2004.
Breast adenocarcinoma liver metastases, in contrast to
colorectal cancer liver metastases, display a non-angiogenic
growth pattern that preserves the stroma and lacks
hypoxia. Br. J. Cancer 90:1429–1436.
8. Van den Eynden, G. G., N. C. Bird, A. W. Majeed, L. S.
Van, L. Y. Dirix, and P. B. Vermeulen. 2012. The
histological growth pattern of colorectal cancer liver
metastases has prognostic value. Clin. Exp. Metastasis
29:541–549.
9. Vermeulen, P. B., C. Colpaert, R. Salgado, R. Royers, H.
Hellemans, E. Van den Heuvel, et al. 2001. Liver
metastases from colorectal adenocarcinomas grow in three
patterns with different angiogenesis and desmoplasia.
J. Pathol. 195:336–342.
10. Naresh, K. N., A. Y. Nerurkar, and A. M. Borges. 2001.
Angiogenesis is redundant for tumour growth in lymph
node metastases. Histopathology 38:466–470.
11. Paulis, Y. W., P. M. Soetekouw, H. M. Verheul,
V. C. Tjan-Heijnen, and A. W. Griffioen. 2010. Signalling
pathways in vasculogenic mimicry. Biochim. Biophys. Acta
1806:18–28.
12. Gianni-Barrera, R., M. Trani, S. Reginato, and A. Banfi.
2011. To sprout or to split? VEGF, Notch and vascular
morphogenesis. Biochem. Soc. Trans. 39:1644–1648.
13. Carmeliet, P., and R. K. Jain. 2011. Molecular mechanisms
and clinical applications of angiogenesis. Nature 473:298–
307.
14. Holash, J., P. C. Maisonpierre, D. Compton, P. Boland,
C. R. Alexander, D. Zagzag, et al. 1999. Vessel cooption,
regression, and growth in tumors mediated by
angiopoietins and VEGF. Science 284:1994–1998.
15. Kusters, B., W. P. Leenders, P. Wesseling, D. Smits,
K. Verrijp, D. J. Ruiter, et al. 2002. Vascular endothelial
growth factor-A(165) induces progression of melanoma
brain metastases without induction of sprouting
angiogenesis. Cancer Res. 62:341–345.
16. Vajkoczy, P., M. Farhadi, A. Gaumann, R. Heidenreich, R.
Erber, A. Wunder, et al. 2002. Microtumor growth
initiates angiogenic sprouting with simultaneous
expression of VEGF, VEGF receptor-2, and angiopoietin-2.
J. Clin. Invest. 109:777–785.
434 ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Vessel Co-option in Human Tumors T. Donnem et al.
17. Zhao, C., H. Yang, H. Shi, X. Wang, X. Chen, Y. Yuan,
et al. 2011. Distinct contributions of angiogenesis and
vascular co-option during the initiation of primary
microtumors and micrometastases. Carcinogenesis
32:1143–1150.
18. Franco, M., M. Paez-Ribes, E. Cortez, O. Casanovas, and
K. Pietras. 2011. Use of a mouse model of pancreatic
neuroendocrine tumors to find pericyte biomarkers of
resistance to anti-angiogenic therapy. Horm. Metab. Res.
43:884–889.
19. Helfrich, I., I. Scheffrahn, S. Bartling, J. Weis, V. von
Felbert, M. Middleton, et al. 2010. Resistance to
antiangiogenic therapy is directed by vascular phenotype,
vessel stabilization, and maturation in malignant
melanoma. J. Exp. Med. 207:491–503.
20. Auf, G., A. Jabouille, S. Guerit, R. Pineau, M. Delugin,
M. Bouchecareilh, et al. 2010. Inositol-requiring enzyme
1alpha is a key regulator of angiogenesis and invasion in
malignant glioma. Proc. Natl. Acad. Sci. USA 107:15553–
15558.
21. Adighibe, O., K. Micklem, L. Campo, M. Ferguson, A. L.
Harris, R. Pozos, et al. 2006. Is nonangiogenesis a novel
pathway for cancer progression? A study using
3-dimensional tumour reconstructions. Br. J. Cancer
94:1176–1179.
22. Passalidou, E., M. Trivella, N. Singh, M. Ferguson, J.
Hu, A. Cesario, et al. 2002. Vascular phenotype in
angiogenic and non-angiogenic lung non-small cell
carcinomas. Br. J. Cancer 86:244–249.
23. Yousem, S. A. 2009. Peripheral squamous cell carcinoma
of lung: patterns of growth with particular focus on
airspace filling. Hum. Pathol. 40:861–867.
24. Sardari, N. P., C. Colpaert, P. Vermeulen, J. Weyler,
F. Pezzella, P. Van Schil, et al. 2008. Different growth
patterns of non-small cell lung cancer represent distinct
biologic subtypes. Ann. Thorac. Surg. 85:395–405.
25. Tunariu, N., S. B. Kaye, and N. M. Desouza. 2012.
Functional imaging: what evidence is there for its utility in
clinical trials of targeted therapies? Br. J. Cancer 106:619–
628.
26. Budde, M. D., E. Gold, E. K. Jordan, and J. A. Frank.
2012. Differential microstructure and physiology of brain
and bone metastases in a rat breast cancer model by
diffusion and dynamic contrast enhanced MRI. Clin. Exp.
Metastasis 29:51–62.
27. Kienast, Y., L. Von Baumgarten, M. Fuhrmann, W. E.
Klinkert, R. Goldbrunner, J. Herms, et al. 2010. Real-time
imaging reveals the single steps of brain metastasis
formation. Nat. Med. 16:116–122.
28. Budde, M. D., E. Gold, E. K. Jordan, M. Smith-Brown,
and J. A. Frank. 2011. Phase contrast MRI is an early
marker of micrometastatic breast cancer development in
the rat brain. NMR Biomed. 25:726–736.
29. Hu, J., F. Bianchi, M. Ferguson, A. Cesario, S Margaritora,
P. Granone, et al. 2005. Gene expression signature for
angiogenic and nonangiogenic non-small-cell lung cancer.
Oncogene 24:1212–1219.
30. Roodink, I., and W. P. Leenders. 2010. Targeted therapies
of cancer: angiogenesis inhibition seems not enough.
Cancer Lett. 299:1–10.
31. di Tomaso, E., M. Snuderl, W. S. Kamoun, D. G. Duda, P.
K. Auluck, L. Fazlollahi, et al. 2011. Glioblastoma
recurrence after cediranib therapy in patients: lack of
“rebound” revascularization as mode of escape. Cancer
Res. 71:19–28.
32. Edel, M., P. Robbins, M. D’Antuono, J. Harvey, J.
Papadimitrion, C. Mitchell, et al. 2000. Assessment of
endothelial cell proliferation in primary breast carcinoma
and its association with axillary lymph node status. Breast
9:28–34.
33. Cascone, T., and J. V. Heymach. 2012. Targeting the
angiopoietin/Tie2 pathway: cutting tumor vessels with a
double-edged sword? J. Clin. Oncol. 30:441–444.
34. Rubenstein, J. L., J. Kim, T. Ozawa, M. Zhang, M.
Westphal, D. F. Deen, et al. 2000. Anti-VEGF antibody
treatment of glioblastoma prolongs survival but results in
increased vascular cooption. Neoplasia 2:306–314.
35. Lu, K. V., J. P. Chang, C. A. Parachoniak, M. K. Aghi,
D. Meyronet, N. Isachenko, et al. 2012. VEGF inhibits
tumor cell invasion and mesenchymal transition through a
MET/VEGFR2 complex. Cancer Cell 22:21–35.
36. de Leite, O. R., A. Hamm, and M. Mazzone. 2011.
Growing tumor vessels: more than one way to skin a cat –
implications for angiogenesis targeted cancer therapies.
Mol. Aspects Med. 32:71–87.
37. Parikh, A. A., and L. M. Ellis. 2011. Circulating angiogenic
factors, tumor cells, and outcome after resection of
metastatic colorectal cancer–what does it mean? Ann. Surg.
Oncol. 18:2111–2113.
38. Leenders, W. P., B. Kusters, K. Verrijp, C. Maass,
P. Wesseling, A. Heerschap, et al. 2004. Antiangiogenic
therapy of cerebral melanoma metastases results in
sustained tumor progression via vessel co-option. Clin.
Cancer Res. 10:6222–6230.
39. Mehta, S., N. P. Hughes, F. M. Buffa, S. P. Li, R. F.
Adams, A. Adwani, et al. 2011. Assessing early therapeutic
response to bevacizumab in primary breast cancer using
magnetic resonance imaging and gene expression profiles.
J. Natl. Cancer Inst. Monogr. 2011:71–74.
40. Smith, A. D., M. L. Lieber, and S. N. Shah. 2010. Assessing
tumor response and detecting recurrence in metastatic
renal cell carcinoma on targeted therapy: importance of
size and attenuation on contrast-enhanced CT. AJR Am. J.
Roentgenol. 194:157–165.
41. Welti, J. C., T. Powles, S. Foo, M. Gourlaouen, N. Preece,
J. Foster, et al. 2012. Contrasting effects of sunitinib
ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 435
T. Donnem et al. Vessel Co-option in Human Tumors
within in vivo models of metastasis. Angiogenesis 15:623–
641.
42. Welti, J. C., M. Gourlaouen, T. Powles, S. C. Kudahetti,
P. Wilson, D. M. Berney, et al. 2011. Fibroblast growth
factor 2 regulates endothelial cell sensitivity to sunitinib.
Oncogene 30:1183–1193.
43. Sitohy, B., J. A. Nagy, S. C. Jaminet, and H. F. Dvorak.
2011. Tumor-surrogate blood vessel subtypes exhibit
differential susceptibility to anti-VEGF therapy. Cancer
Res. 71:7021–7028.
44. Hu, Y. L., M. Delay, A. Jahangiri, A-M. Molinaro, S. D.
Rose, W. S. Carbonell, et al. 2012. Hypoxia-induced
autophagy promotes tumor cell survival and adaptation to
antiangiogenic treatment in glioblastoma. Cancer Res.
72:1773–1783.
45. Shojaei, F., X. Wu, A. K. Malik, C. Zhong, M. E. Baldwin,
S. Schanz, et al. 2007. Tumor refractoriness to anti-VEGF
treatment is mediated by CD11b+Gr1+ myeloid cells. Nat.
Biotechnol. 25:911–920.
46. Allegra, C. J., G. Yothers, M. J. O’Connell, S. Sharif, N. J.
Petrelli, S. H. Lopa, et al. 2013. Bevacizumab in stage II-III
colon cancer: 5-year update of the National Surgical
Adjuvant Breast and Bowel Project C-08 trial. J. Clin.
Oncol. 31:359–364.
47. Carbone, D. P., and E. Felip. 2011. Adjuvant therapy in
non-small cell lung cancer: future treatment prospects and
paradigms. Clin. Lung Cancer 12:261–271.
48. Oyan, B. 2012. Why do targeted agents not work in the
adjuvant setting in colon cancer? Expert Rev. Anticancer
Ther. 12:1337–1345.
49. Carbonell, W. S., O. Ansorge, N. Sibson, and R. Muschel.
2009. The vascular basement membrane as “soil” in brain
metastasis. PLoS One 4:e5857.
50. Winkler, F., Y. Kienast, M. Fuhrmann, L. von Baumgarten,
S. Burgold, G. Mitteregger, et al. 2009. Imaging glioma cell
invasion in vivo reveals mechanisms of dissemination and
peritumoral angiogenesis. Glia 57:1306–1315.
51. Reiss, Y., A. Knedla, A. O. Tal, M. H. Schmidt, M. Jugold,
F. Kiessling, et al. 2009. Switching of vascular phenotypes
within a murine breast cancer model induced by
angiopoietin-2. J. Pathol. 217:571–580.
52. Offersen, B. V., P. Pfeiffer, P. Andreasen, and J.
Overgaard. 2007. Urokinase plasminogen activator and
plasminogen activator inhibitor type-1 in nonsmall-cell
lung cancer: relation to prognosis and angiogenesis. Lung
Cancer 56:43–50.
53. Arismendi-Morillo, G., and A. Castellano. 2005. Tumoral
micro-blood vessels and vascular microenvironment in
human astrocytic tumors. A transmission electron
microscopy study. J. Neurooncol. 73:211–217.
54. Renyi-Vamos, F., J. Tovari, J. Fillinger, J. Timar, S. Paku,
I. Kenessey, et al. 2005. Lymphangiogenesis correlates with
lymph node metastasis, prognosis, and angiogenic
phenotype in human non-small cell lung cancer. Clin.
Cancer Res. 11:7344–7353.
55. Paku, S., L. Kopper, and P. Nagy. 2005. Development of
the vasculature in “pushing-type” liver metastases of an
experimental colorectal cancer. Int. J. Cancer 115:893–
902.
56. Shieh, Y. S., H. S. Lee, S. G. Shiah, Y. W. Chu, C. W. Wu,
and L. C. Chang. 2004. Role of angiogenic and
non-angiogenic mechanisms in oral squamous cell
carcinoma: correlation with histologic differentiation and
tumor progression. J. Oral Pathol. Med. 33:601–606.
57. Sardari, N. P., C. Colpaert, B. Blyweert, B. Kui, P.
Vermeulen, M. Ferguson, et al. 2004. Prognostic value of
nonangiogenic and angiogenic growth patterns in
non-small-cell lung cancer. Br. J. Cancer 91:1293–1300.
58. Guedj, N., A. Couvelard, G. Arcangeli, S. Dubois, G.
Thabut, G. Leseche, et al. 2004. Angiogenesis and
extracellular matrix remodelling in bronchioloalveolar
carcinomas: distinctive patterns in mucinous and
non-mucinous tumours. Histopathology 44:251–256.
59. Kaicker, S., K. W. McCrudden, L. Beck, T. New, J. Huang,
J. S. Frischer, et al. 2003. Thalidomide is anti-angiogenic
in a xenograft model of neuroblastoma. Int. J. Oncol.
23:1651–1655.
60. Leenders, W., B. Kusters, J. Pikkemaat, P. Wesseling, D.
Ruiter, A. Heerschap, et al. 2003. Vascular endothelial
growth factor-A determines detectability of experimental
melanoma brain metastasis in GD-DTPA-enhanced MRI.
Int. J. Cancer 105:437–443.
436 ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Vessel Co-option in Human Tumors T. Donnem et al.
